Challenges in establishing potent cancer chemotherapy using newly synthesized 1,5-Diaryl-3-Oxo-1,4-Pentadiene analogs of curcumin

Curcumin: Biosynthesis, Medicinal Uses and Health Benefits

Volumn , Issue , 2012, Pages 177-191

  Shibata, Hiroyuki ^a   Iwabuchi, Yoshiharu ^b  

^a AKITA UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892206319     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (44)

1. Singh S. (2007). From exotic spice to modern drug? Cell. 130, 765-768.
2. Steward WP., Gescher AJ. (2008). Curcumin in cancer Mol. Nutr. Food Res. 52, 1005- 1009.
3. Singh S., Aggarwal BB. (1995) Activation of transcription factor NF-nB is suppressed by curcumin (diferuloylmethane). J. Biol. Chem. 270, 24995-25000.
4. Surh YJ., Han SS., Keum YS., Seo HJ., Lee SS. (2000). Inhibitory effects of curcumin and capsaicin on phorbol ester-induced activation of eukaryotic transcription factors, NF-nB and AP-1. Biofactors. 1, 107-112.
5. Jaiswal AS., Marlow BP., Gupta N., Narayan S. (2002). β-Catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene. 21, 8414-8427.
6. Lee JY., Lee YM., Chang GC., et al. (2011). Curcumin Induces EGFR Degradation in Lung Adenocarcinoma and Modulates p38 Activation in Intestine: The Versatile Adjuvant for Gefitinib Therapy. PLoS One. 6, e23756.
7. Ravindran J., Prasad S., Aggarwal BB. (2009). Curcumin and cancer AAPS J. 11, 495- 510.
8. Bill MA., Fuchs JR., Li C., et al. (2010). The small molecule curcumin Mol. Cancer. 9, 165.
9. Binion DG., Otterson MF., Rafiee P. (2008). Curcumin inhibits VEGF-mediated angiogenesis Gut. 57, 1509-1517.
10. Lu HF., Lai KC., Hsu SC., et al. (2009). Curcumin induces apoptosis Oncol. Rep., 22, 97-104.
11. Jung EM., Lim JH., Lee TJ., et al. (2005). Curcumin sensitizes tumor Carcinogenesis. 26, 1905-1913.
12. Park MJ, Kim EH, Park IC et al. (2002). Curcumin inhibits cell cycle progression of immortalized human umbilical vein endothelial (ECV304) cells by upregulating cyclin dependent kinase inhibitor, p21WAF1 / CIP1, p27KIP1 and p53. Int. J. Oncol., 21, 379-383.
13. Lin HJ., Su CC., Lu HF., et al. (2010) Curcumin blocks migration Oncol. Rep., 23, 665- 670.
14. Lin SS., Lai KC., Hsu SC., et al. (2009). Curcumin inhibits the migration Cancer Lett., 285, 127-133.
15. Shehzad A., Wahid F., Lee YS. (2010) Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch. Pharm. Chem. Life Sci., 000, 1-11.
16. Kanai M., Yoshimura K., Asada M., et al. (2011). A phase I/II study of gemcitabinebased chemotherapy Cancer Chemother. Pharmacol., 68, 157-164.
17. Dhillon N., Aggarwal BB., Newman RA., et al. (2008). Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin. Cancer Res., 14, 4491-4499.
18. Ohori H., Yamakoshi H., Tomizawa M., et al. (2006). Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer. Mol. Cancer Ther, 5, 2563-2571.
19. Yamakoshi H., Ohori H., Kudo C., et al. (2010). Structure-activity relationship of C5- curcuminoids and synthesis of their molecular probes thereof. Bioorganic & Medicinal Chemistry, 18, 1083-1092.
20. Kudo C., Yamakoshi H., Sato A., et al. (2011). Synthesis of 86 species of 1,5-diaryl-3- oxo-1,4-pentadienes analogs of curcumin can yield a good lead in vivo. BMC Pharmacology, 11, 4.
21. Sato A., Kudo C., Yamakoshi H., et al. (2011). Curcumin analog GO-Y030 is a novel inhibitor of IKKβ that suppresses NF-?B signaling and induces apoptosis. Cancer Sci., 102, 1045-1051.
22. Lin L., Liu Y., Li H., et al. (2011). Targeting colon Br. J. Cancer. 105, 212-220.
23. Hutzen B., Friedman L., Sobo M., et al. (2009). Curcumin analogue GO-Y030 inhibits STAT3 activity and cell growth Int. J. Oncol., 35, 867-872.
24. Kudo C., Yamakoshi H., Sato A., et al. (2011). GO-Y030 and GO-Y078, are multitargted agents with enhanced abiities for multiple myeloma. Anticancer Research, 31, 3719-3729.
25. Takezawa K., Okamoto I., Yonesaka K., et al. (2009). Sorafenib inhibits non-small cell lung cancer Cancer Res., 69, 6515-6521.
26. Castellano E., Downward J. (2011). RAS Interaction with PI3K Genes Cancer., 2, 261- 274.
27. Cen L., Hutzen B., Ball S., et al. (2009). New structural analogues of curcumin exhibit potent growth suppressive activity in human colorectal carcinoma cells. BMC Cancer, 9, 99.
28. Kim R. (2005). Unknotting the roles of Bcl-2 and Bcl-xL in cell death Biochem. Biophys. Res. Commun., 333, 336-343.
29. Choi HJ., Lee JH., Park SY., et al. (2009). STAT3 is involved in phosphatidic acid Exp. Mol. Med., 41, 94-101.
30. Grad JM., Zeng XR., Boise LH. (2000). Regulation of Bcl-xL: a little bit of this and a little bit of STAT. Curr. Opin. Oncol., 12, 543-549.
31. Gyrd-Hansen M., Meier P. (2010). IAPs: from caspase inhibitors to modulators of NFkappaB, inflammation Nat. Rev. Cancer. 10, 561-574.
32. Jin HS., Lee DH., Kim DH., et al. (2009). cIAP1, cIAP2, and XIAP act cooperatively via nonredundant pathways Cancer Res., 69, 1782-1791.
33. Wang XH, Sun X, Meng XW, et al. (2010). β-catenin siRNA Oncol. Rep. 24, 1093- 1099.
34. Mita AC., Mita MM., Nawrocki ST., et al. (2008). Survivin: key regulator of mitosis Clin. Cancer Res., 14, 5000-5005.
35. Aggarwal BB, Kunnumakkara AB, Harikumar KB, et al. (2009). Signal transducer Ann. N. Y. Acad. Sci. 1171, 59-76.
36. Shan BE., Wang MX., Li RQ. (2009). Quercetin inhibit human Cancer Invest. 27, 604- 612.
37. Soussi T, Wiman KG. (2007). Shaping genetic alteration Cancer Cell. 12, 30.
38. Elrod HA., Sun SY. (2008). Modulation of death receptors by cancer therapeutic agents. Cancer Biol. Ther., 7, 163-173.
39. Jung EM., Lim JH., Lee TJ., et al. (2005). Curcumin sensitizes tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL)-inducedapoptosis through reactive oxygen species-mediated upregulation of death receptor 5 (DR5). Carcinogenesis, 26, 1905- 1913.
40. Yamakoshi H., Kanoh N., Kudo G., et al. (2010). KSRP/FUBP2 is a binding protein of GO-Y086, a cytotoxic curcumin analogue. ACS Med. Chem. lett. 1, 273-276.
41. Trabucchi M., Briata P., Filipowicz W., et al. (2011). KSRP Promotes the Maturation of a Group of miRNA Precuresors. Adv. Exp. Med. Biol. 700, 36-42.
42. Shibata H., Yamakoshi H., Sato A., et al. (2009). Newly synthesized curcumin Cancer Sci., 100, 956-960.
43. Boseley S. New treatments raise hope of cutting sleeping sickness deaths. 2009 May 15, Available from http://www.guardian
44. Newson J., Mahan SM., Black SJ. (1990). Synthesis and secretion Parasite Immunol. 12, 125-139.